TW200738228A - Neramexane modified release matrix tablet - Google Patents

Neramexane modified release matrix tablet

Info

Publication number: TW200738228A
Authority: TW; Taiwan
Prior art keywords: modified release; neramexane; dosage forms; release matrix; dementia
Prior art date: 2005-11-30

Application number

TW095144015A

Other languages

English (en)

Inventor

Bernhard Hauptmeier

Andreas Becker

Original Assignee

Merz Pharma Gmbh & Co Kgaa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-30

Filing date

2006-11-28

Publication date

2007-10-16

2006-11-28 Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa

2007-10-16 Publication of TW200738228A publication Critical patent/TW200738228A/zh

Links

OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 title abstract 3
229950004543 neramexane Drugs 0.000 title abstract 3
239000013563 matrix tablet Substances 0.000 title 1
239000002552 dosage form Substances 0.000 abstract 3
208000024827 Alzheimer disease Diseases 0.000 abstract 2
208000004296 neuralgia Diseases 0.000 abstract 2
208000021722 neuropathic pain Diseases 0.000 abstract 2
238000011340 continuous therapy Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000873 masking effect Effects 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW095144015A 2005-11-30 2006-11-28 Neramexane modified release matrix tablet TW200738228A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US74097505P	2005-11-30	2005-11-30

Publications (1)

Publication Number	Publication Date
TW200738228A true TW200738228A (en)	2007-10-16

Family

ID=37698309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095144015A TW200738228A (en)	2005-11-30	2006-11-28	Neramexane modified release matrix tablet

Country Status (14)

Country	Link
US (1)	US20070141148A1 (zh)
EP (1)	EP1959941A1 (zh)
JP (2)	JP5276989B2 (zh)
KR (1)	KR101084832B1 (zh)
CN (1)	CN101300001B (zh)
AR (1)	AR056824A1 (zh)
AU (1)	AU2006319411B8 (zh)
BR (1)	BRPI0619384A2 (zh)
CA (1)	CA2624589C (zh)
IL (1)	IL191578A0 (zh)
RU (1)	RU2422135C2 (zh)
TW (1)	TW200738228A (zh)
WO (1)	WO2007062815A1 (zh)
ZA (1)	ZA200803172B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200916091A (en) *	2007-06-08	2009-04-16	Merz Pharma Gmbh & Amp Co Kgaa	Neramexane for the treatment of nystagmus
ATE532507T1 (de)	2007-09-12	2011-11-15	Merz Pharma Gmbh & Co Kgaa	Neramexane zur behandlung von subakuten tinnitus
RU2446794C2 (ru) *	2007-09-12	2012-04-10	Мерц Фарма Гмбх Унд Ко. Кгаа	Терапия с интервалами для лечения тиннитуса
TW201010691A (en) *	2008-06-12	2010-03-16	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) *	2008-06-26	2010-02-16	Merz Pharma Gmbh & Co Kgaa	Pharmaceutical compositions comprising aminocyclohexane derivatives
RU2011113733A (ru) *	2008-09-10	2012-10-20	Мерц Фарма Гмбх Унд Ко. Кгаа (De)	Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
CA2737335C (en) *	2008-12-19	2013-10-01	Merz Pharma Gmbh & Co. Kgaa	1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
TWI432188B (zh) *	2008-12-19	2014-04-01	Merz Pharma Gmbh & Co Kgaa	供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN102438981B (zh)	2009-04-17	2015-04-22	德国麦氏大药厂	1-氨基-1,3,3,5,5-五甲基环己烷甲磺酸盐的合成
CA2765609A1 (en) *	2009-06-29	2011-01-06	Merz Pharma Gmbh & Co. Kgaa	Method of preparing neramexane
EP2448910B1 (en) *	2009-06-29	2013-05-15	Merz Pharma GmbH & Co. KGaA	Method of preparing neramexane
WO2011000541A1 (en) *	2009-06-29	2011-01-06	Merz Pharma Gmbh & Co Kgaa	Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
US20120237563A1 (en) *	2009-08-21	2012-09-20	University Of Florida Research Foundation Inc.	Controlled-release formulations of anabaseine compounds and uses thereof
JP2013505222A (ja) *	2009-09-18	2013-02-14	ビーエーエスエフソシエタス・ヨーロピア	親水性ポリマーと組み合わせたポリエーテルに基づく両親媒性コポリマーを含有する速溶性固体医薬製剤
US20110294890A1 (en)	2010-05-28	2011-12-01	Merz Pharma Gmbh & Co. Kgaa	Neramexane for the treatment or prevention of inner ear disorders
MX2012012318A (es)	2010-06-18	2012-11-21	Merz Pharma Gmbh & Co Kgaa	Formulaciones en gel para el uso topico de derivados de 1-amino-alquiciclohexano.
EP2585049A1 (en)	2010-06-24	2013-05-01	Merz Pharma GmbH & Co. KGaA	Neramexane multiple unit dosage form
EP2621509A4 (en) *	2010-09-15	2016-08-03	Synergy Pharmaceuticals Inc	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE
JP6084931B2 (ja)	2011-01-20	2017-02-22	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
HK1216839A1 (zh) *	2013-06-12	2016-12-09	Novartis Ag	调整释放制剂
WO2021245199A1 (en) *	2020-06-03	2021-12-09	Københavns Universitet	Glp1r agonist nmdar antagonist conjugates
CU24720B1 (es) *	2020-11-24	2024-10-09	Centro De Neurociencias De Cuba	Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CN115507773B (zh) *	2021-06-07	2025-02-18	广州视源电子科技股份有限公司	三维测量方法及系统
AU2022400245A1 (en) *	2021-12-02	2024-05-30	Københavns Universitet	Peptide-drug conjugates for treatment of neurodegenerative diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3007387B2 (ja) *	1990-07-16	2000-02-07	エーザイ株式会社	徐放性製剤用基剤粉末
DE4443358A1 (de) *	1994-12-06	1996-06-13	Basf Ag	Depot-Arzneimittel
UA61962C2 (uk) *	1997-06-30	2003-12-15	Мерц Фарма Гмбх Унд Ко. Кгаа	Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
US20030050620A1 (en) *	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
AU2003287301A1 (en) *	2002-10-31	2004-06-07	Alza Corporation	Dosage form providing ascending release of liquid formulation
US7704528B2 (en) *	2003-05-05	2010-04-27	Isp Investments Inc.	Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability
MXPA05012493A (es) *	2003-05-27	2006-05-25	Forest Laboratories	Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
AU2004258751C1 (en) *	2003-07-28	2008-07-17	Merz Pharma Gmbh & Co. Kgaa	The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
US20050123502A1 (en) *	2003-10-07	2005-06-09	Chan Shing Y.	Nicotine containing oral compositions
US20050113458A1 (en) *	2003-10-22	2005-05-26	Forest Laboratories, Inc.	Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
TW200531680A (en) *	2004-03-03	2005-10-01	Merz Pharma Gmbh & Co Kgaa	Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
WO2005102289A1 (en) *	2004-03-24	2005-11-03	Lupin Limited	Clarithromycin extended release formulation
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP2008503475A (ja) *	2004-06-17	2008-02-07	フォーレストラボラトリーズ，インコーポレイテッド	メマンチンの放出が改変された製剤
CA2588295C (en) *	2004-11-23	2013-10-22	Adamas Pharma, Llc	Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) *	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) *	2004-11-24	2006-06-01	Neuromolecular Pharmaceuticals, Inc.	Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20060205822A1 (en) *	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EA013474B1 (ru) *	2005-06-16	2010-04-30	Форест Лэборэтериз, Инк.	Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина

2006
- 2006-11-27 US US11/604,986 patent/US20070141148A1/en not_active Abandoned
- 2006-11-28 TW TW095144015A patent/TW200738228A/zh unknown
- 2006-11-29 CA CA2624589A patent/CA2624589C/en not_active Expired - Fee Related
- 2006-11-29 KR KR1020087013022A patent/KR101084832B1/ko not_active Expired - Fee Related
- 2006-11-29 JP JP2008542654A patent/JP5276989B2/ja not_active Expired - Fee Related
- 2006-11-29 AU AU2006319411A patent/AU2006319411B8/en not_active Ceased
- 2006-11-29 RU RU2008126212/15A patent/RU2422135C2/ru not_active IP Right Cessation
- 2006-11-29 WO PCT/EP2006/011438 patent/WO2007062815A1/en not_active Ceased
- 2006-11-29 CN CN2006800406697A patent/CN101300001B/zh not_active Expired - Fee Related
- 2006-11-29 EP EP06818895A patent/EP1959941A1/en not_active Withdrawn
- 2006-11-29 BR BRPI0619384-6A patent/BRPI0619384A2/pt not_active IP Right Cessation
- 2006-11-30 AR ARP060105301A patent/AR056824A1/es not_active Application Discontinuation
2008
- 2008-04-10 ZA ZA200803172A patent/ZA200803172B/xx unknown
- 2008-05-20 IL IL191578A patent/IL191578A0/en unknown
2013
- 2013-03-05 JP JP2013042711A patent/JP5745556B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2007062815A1 (en)	2007-06-07
RU2422135C2 (ru)	2011-06-27
AU2006319411A1 (en)	2007-06-07
CA2624589A1 (en)	2007-06-07
AU2006319411B8 (en)	2010-10-21
KR20080069218A (ko)	2008-07-25
KR101084832B1 (ko)	2011-11-21
US20070141148A1 (en)	2007-06-21
ZA200803172B (en)	2009-03-25
JP5745556B2 (ja)	2015-07-08
IL191578A0 (en)	2008-12-29
CN101300001B (zh)	2011-12-14
AR056824A1 (es)	2007-10-24
HK1124762A1 (zh)	2009-07-24
EP1959941A1 (en)	2008-08-27
AU2006319411B2 (en)	2010-09-16
RU2008126212A (ru)	2010-01-10
CN101300001A (zh)	2008-11-05
CA2624589C (en)	2011-05-24
BRPI0619384A2 (pt)	2011-10-04
JP5276989B2 (ja)	2013-08-28
JP2013136620A (ja)	2013-07-11
JP2009517420A (ja)	2009-04-30

Publication	Publication Date	Title
CY1115484T1 (el)	2017-01-04	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
TW200626159A (en)	2006-08-01	Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
WO2008021113A3 (en)	2008-08-14	Transdermal methods and systems for treating alzheimer's disease
WO2008131057A3 (en)	2009-12-03	Sustained release formulations of opioid and nonopioid analgesics
WO2003005968A3 (en)	2003-10-16	Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa
EP1933833B8 (en)	2011-09-14	Therapy for the treatment of overactive bladder
MXPA05003253A (es)	2005-06-08	Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2008142572A3 (en)	2009-02-12	Controlled release tablet formulation containing magnesium aluminometasilicate
AR056824A1 (es)	2007-10-24	Tableta de neramexano con matriz de liberacion modificada
UA104988C2 (uk)	2014-04-10	Похідні піроніндолу та спосіб їх отримання
PT2205279E (pt)	2011-07-11	Associação farmacêutica de aliscireno e valsartan
TW200806289A (en)	2008-02-01	Sustained-release formulation of zonisamide
MX2011011459A (es)	2011-11-18	Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MXPA05012358A (es)	2006-02-02	Combinacion farmaceutica que comprende modafinilo y otra droga.
PT1425005E (pt)	2006-09-29	Composicao farmaceutica que compreende lumiracoxib
SG158863A1 (en)	2010-02-26	Intravenous formulations of pde-5 inhibitors
BRPI0513598A (pt)	2008-05-13	formas de dosagem em comprimidos revestidos de liberação entérica
PT1656131E (pt)	2011-06-07	Utilização de betaína para tratar claudicação intermitente
MXPA05008843A (es)	2005-10-18	Sistema terapeutico que comprende amoxicilina y acido clavulanico.
TW200616644A (en)	2006-06-01	Medicine for prevention or treatment of diabetes
WO2016122288A3 (ko)	2016-11-10	베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2007081486A3 (en)	2008-04-10	Oral administration of defensins to treat intestinal diseases
UA90504C2 (ru)	2010-05-11	Лекарственное средство для лечения заболеваний дыхательных путей
WO2005092062A3 (en)	2006-08-03	Compounds for neurodegenerative disorders
MA31227B1 (fr)	2010-03-01	Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.